Q32 Bio Inc. and Homology Medicines, Inc. have agreed to a definitive merger agreement in an all-stock transaction. The consolidated company will keep the Q32 Bio Inc. name and be headquartered in Waltham, Massachusetts. Q32 has also regained all rights from Amgen for bempikibart, a drug in Phase 2 trials for treating autoimmune diseases atopic dermatitis and alopecia areata. Concurrently, Q32 Bio agreed to a $42 million private investment to support clinical development.
RustDuck: The Botnet That’s Still Small but Engineering Like It Plans to Grow – Security Affairs
RustDuck: The Botnet That’s Still Small but Engineering Like It Plans to Grow Security Affairs
